{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T03:12:32Z","timestamp":1792725152155,"version":"4.5.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ejca.2021.01.013","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T01:35:49Z","timestamp":1615253749000},"page":"170-181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"special_numbering":"C","title":["Hematological immune related adverse events after treatment with immune checkpoint inhibitors"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-5289","authenticated-orcid":false,"given":"Rafaela","family":"Kramer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Zaremba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvaro","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma","family":"Ugurel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7575-6230","authenticated-orcid":false,"given":"Jessica C.","family":"Hassel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4310-4822","authenticated-orcid":false,"given":"Martin","family":"Salzmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Gesierich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3769-490X","authenticated-orcid":false,"given":"Alison","family":"Weppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lavinia","family":"Spain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Dudda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pf\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8716-9401","authenticated-orcid":false,"given":"Adriana","family":"Hepner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina V.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo S.","family":"Carlino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Enokida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schlaak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8857-1243","authenticated-orcid":false,"given":"Kinan","family":"Hayani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedegund","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-5132","authenticated-orcid":false,"given":"Lydia","family":"Reinhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0019-2770","authenticated-orcid":false,"given":"Thomas","family":"Eigentler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carola","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3680-3521","authenticated-orcid":false,"given":"Lisa","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2021.01.013_bib1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.013_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrc2051","article-title":"Immunostimulatory monoclonal antibodies for cancer therapy","volume":"7","author":"Melero","year":"2007","journal-title":"Nat Rev Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2021.01.013_bib4","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus Placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.013_bib5","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2021.01.013_bib6","first-page":"119","article-title":"Checkpoint-inhibitoren","volume":"116","author":"Heinzerling","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.ejca.2021.01.013_bib7","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib8","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib9","doi-asserted-by":"crossref","first-page":"230","DOI":"10.6004\/jnccn.2020.0012","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2021.01.013_bib10","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination","volume":"13","author":"Boutros","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib11","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib12","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.autrev.2018.01.003","article-title":"Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors","volume":"17","author":"Lidar","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ejca.2021.01.013_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s00262-017-2069-9","article-title":"Characterization of\u00a0arthralgia induced by PD-1 antibody treatment in patients with\u00a0metastasized cutaneous malignancies","volume":"67","author":"Buder-Bakhaya","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2021.01.013_bib14","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejca.2017.05.032","article-title":"Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1\/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis","volume":"82","author":"Le Burel","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib15","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.013_bib16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.01.013_bib17","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/S2352-3026(18)30175-3","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.ejca.2021.01.013_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","article-title":"Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?","volume":"122","author":"Michot","year":"2019","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000495980","article-title":"Nivolumab induced lethal aplastic anemia in a patient with metastatic melanoma","volume":"12","author":"Rouvinov","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib20","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/annonc\/mdx177","article-title":"Lethal aplastic anemia caused by dual immune checkpoint blockade in metastatic melanoma","volume":"28","author":"Helgadottir","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejca.2021.01.013_bib22","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s10875-017-0456-9","article-title":"Autoimmune cytopenias and associated conditions in CVID: a report from the USIDNET registry","volume":"38","author":"Feuille","year":"2018","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.ejca.2021.01.013_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2018.07.129","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib24","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1634\/theoncologist.2018-0574","article-title":"Hematologic complications of immune checkpoint inhibitors","volume":"24","author":"Davis","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2021.01.013_bib25","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/ejh.13187","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review","volume":"102","author":"Tanios","year":"2019","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.ejca.2021.01.013_bib26","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/ajh.25448","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ejca.2021.01.013_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(16)30098-5","article-title":"Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1\/2 trial","volume":"17","author":"Antonia","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib28","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3389\/fphar.2019.00454","article-title":"Hematological side effects of immune checkpoint inhibitors: the example of immune-related thrombocytopenia","volume":"10","author":"Calvo","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ejca.2021.01.013_bib29","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1177\/1078155211411001","article-title":"Ipilimumab-induced thrombocytopenia in a patient with metastatic melanoma","volume":"18","author":"Ahmad","year":"2012","journal-title":"J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2021.01.013_bib30","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.3109\/0284186X.2014.1002572","article-title":"Thrombocytopenia due to low-dose colchicine therapy: a possible drug interaction with nivolumab and implications for supportive care","volume":"54","author":"Solomon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2015.10.073","article-title":"Two cases of immune thrombocytopenia associated with pembrolizumab","volume":"54","author":"Le Roy","year":"2016","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib32","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1159\/000479237","article-title":"A case of immune thrombocytopenia as a rare side effect of an immunotherapy with PD1-blocking agents for metastatic melanoma","volume":"44","author":"Pf\u00f6hler","year":"2017","journal-title":"Transfus Med Hemotherapy Off Organ Der Dtsch Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie"},{"key":"10.1016\/j.ejca.2021.01.013_bib33","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1159\/000452296","article-title":"Autoimmune hemolytic anemia as a complication of nivolumab therapy","volume":"9","author":"Palla","year":"2016","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib34","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/CMR.0000000000000232","article-title":"Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma","volume":"26","author":"Kong","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejca.2021.01.013_bib35","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1002\/hon.2338","article-title":"Autoimmune hemolytic anemia after nivolumab treatment in Hodgkin lymphoma responsive to immunosuppressive treatment. A case report","volume":"35","author":"Tardy","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib36","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1159\/000500856","article-title":"AIHA and pancytopenia as complications of pembrolizumab therapy for metastatic melanoma: a case report","volume":"12","author":"Ni","year":"2019","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib37","first-page":"OP2000047","article-title":"Refractory autoimmune hemolytic anemia and pure red cell Aplasia secondary to immunotherapy requiring prolonged immunosuppression","author":"Hall","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.ejca.2021.01.013_bib38","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40425-018-0384-0","article-title":"Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab","volume":"6","author":"Hantel","year":"2018","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2021.01.013_bib39","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1159\/000507281","article-title":"Hemophagocytic lymphohistiocytosis secondary to PD-1 and IDO inhibition in a patient with refractory glioblastoma","volume":"13","author":"Thummalapalli","year":"2020","journal-title":"Case Rep Oncol"},{"key":"10.1016\/j.ejca.2021.01.013_bib40","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/CJI.0000000000000194","article-title":"Management of immune-mediated cytopenias in the era of cancer immunotherapy: a report of 4 cases","volume":"41","author":"Sun","year":"2018","journal-title":"J Immunother"},{"key":"10.1016\/j.ejca.2021.01.013_bib41","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1097\/CAD.0000000000000520","article-title":"Severe complicated neutropenia in two patients with metastatic non-small-cell lung cancer treated with nivolumab","volume":"28","author":"Turgeman","year":"2017","journal-title":"Anti Canc Drugs"},{"key":"10.1016\/j.ejca.2021.01.013_bib42","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/1078155217726159","article-title":"Nivolumab-induced aplastic anemia: a case report and literature review","volume":"25","author":"Comito","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.ejca.2021.01.013_bib43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.21307\/immunohematology-2019-004","article-title":"Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation","volume":"33","author":"Cooling","year":"2017","journal-title":"Immunohematology"},{"key":"10.1016\/j.ejca.2021.01.013_bib44","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1056\/NEJMc1110923","article-title":"Hemophilia A induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2021.01.013_bib45","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions","volume":"57","author":"Hassel","year":"2017","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2021.01.013_bib46","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1759-7714.13281","article-title":"Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events","volume":"11","author":"Zhuang","year":"2020","journal-title":"Thorac Canc"},{"key":"10.1016\/j.ejca.2021.01.013_bib47","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.2217\/fon-2019-0101","article-title":"Cancer immunotherapy-associated hypophysitis","volume":"15","author":"Castillero","year":"2019","journal-title":"Future Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000241?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804921000241?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:31:22Z","timestamp":1760733082000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804921000241"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":47,"alternative-id":["S0959804921000241"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2021.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}